As of June 13, 2025, Hunan Jingfeng Pharmaceutical Co Ltd (000908.SZ) reports a ROE (Return on Equity) of 186.20%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Hunan Jingfeng Pharmaceutical Co Ltd's ROE (Return on Equity)
Over recent years, Hunan Jingfeng Pharmaceutical Co Ltd's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | 186.20% |
| 2023-12-31 | 335.13% |
| 2022-12-31 | -74.38% |
| 2021-12-31 | -53.42% |
| 2020-12-31 | -219.04% |
This slight downward trend highlights how Hunan Jingfeng Pharmaceutical Co Ltd manages its efficiency in generating profits from shareholders' equity over time.
Comparing Hunan Jingfeng Pharmaceutical Co Ltd's ROE (Return on Equity) to Peers
To better understand Hunan Jingfeng Pharmaceutical Co Ltd's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Hunan Jingfeng Pharmaceutical Co Ltd (000908.SZ) | 186.20% |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181.SZ) | 18.34% |
| Tibet Weixinkang Medicine Co Ltd (603676.SS) | 17.77% |
| Hunan Fangsheng Pharmaceutical Co Ltd (603998.SS) | 15.73% |
| Changzhou Qianhong Biopharma Co Ltd (002550.SZ) | 14.14% |
| Hunan Hansen Pharmaceutical Co Ltd (002412.SZ) | 10.00% |
Compared to its competitors, Hunan Jingfeng Pharmaceutical Co Ltd's ROE (Return on Equity) is higher than all peers, suggesting efficient use of shareholder equity to generate profits.